Chemodex

Ulipristal acetate

CHF 170.00
In stock
CDX-U0027-M05050 mgCHF 170.00
CDX-U0027-M100100 mgCHF 285.00
More Information
Product Details
Synonyms (11β)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; CDB-2914; HRP 2000; RU 44675
Product Type Chemical
Properties
Formula C30H37NO4
MW 475.62
CAS 126784-99-4
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance White to light yellow crystalline powder.
Solubility Soluble in DMSO (30mg/ml), ethanol (30mg/ml) or DMF (30mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key OOLLAFOLCSJHRE-ZHAKMVSLSA-N
Smiles O=C1CCC2=C3[C@@]([C@@](CC[C@]4(OC(C)=O)C(C)=O)([H])[C@]4(C)C[C@]3([H])C5=CC=C(N(C)C)C=C5)([H])CCC2=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to the human progesterone receptors PR-A and PR-B (EC50s=8.5 and 7.7nM, respectively), rabbit uterine PR (EC50=13.6nM), and rabbit thymic glucocorticoid receptor (GR; EC50=15.4nM). It is selective for human progesterone receptors over the human estrogen receptor (ER; EC50>10,000nM). It inhibits growth of IGROV-1 and SKOV3 human ovarian cancer cells (IC50s=15.5 and 31.5μM, respectively) even after resistance to combined cisplatin and paclitaxel treatment has developed. Ulipristal acetate reverses the proliferative effect of progesterone on patient-derived germline mutant BRCA1 breast tissue xenografts in ovariectomized athymic mice. Formulations containing ulipristal acetate have been used as emergency contraceptives and to treat uterine fibroids.

Product References

(1) B.J. Attardi, et al.; J. Steroid Biochem. Mol. Biol. 88, 277 (2004) | (2) P.A. Orihuela; Curr. Opin. Investig. Drugs 8, 859 (2007) (Review) | (3) K. McKeage & J.D. Croxtall; Drugs 71, 935 (2011) (Review) | (4) B. Mozzanega, et al.; Trends Pharmacol. Sci. 34, 195 (2013) | (5) S. Nallasamy, et al.; Reprod. Sci. 20, 371 (2013) | (6) C.D. Gamarra-Luques, et al.; J. Ovarian Res. 7, 45 (2014) | (7) N. Esber, et al.; PLoS One 10, e0140795 (2015) | (8) L. Communcal, et al.; Oncotarget 7, 45317 (2016)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.